首页 列表页面
Calquence一线治疗CLL的ELEVATE TN Ⅲ期临床试验中期分析结果非常亮眼。
第一现场
AbbVie and Scripps Research announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis
新闻
Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies
新闻
93 Percent of Patients Treated with Investigational KTE-X19 Achieved Response, Including 67 Percent with a Complete Response
新闻
Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity
新闻
CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18
新闻
Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients
新闻
CS1001在rr-ENKTL患者中表现出良好的抗肿瘤活性， 患者获得较高的CR，持久的缓解及生存获益
新闻